[目的]比较常规治疗联用帕罗西汀或米氮平,对功能性消化不良(FD)伴体重减轻的治疗效果。[方法]随机对照法,60例FD伴体重减轻患者分入米氮平组(常规治疗联用米氮平)、帕罗西汀组(常规治疗联用帕罗西汀)和对照组(常规治疗),嘱定期服药、门诊复诊或社区随访,观察4周、8周后各组患者尼平消化不良指数(NDI)和体重情况。[结果]治疗前组间NDI和体重无显著差异,治疗4周后NDI评分:米氮平组<帕罗西汀组<对照组(P<0.05),体重:组间无显著差异(P>0.05);治疗8周后,NDI评分:米氮平组<帕罗西汀组<帕罗西汀组(P<0.05),体重:米氮平组高于帕罗西汀组和对照组(P<0.05)。米氮平/帕罗西汀组出现轻微不良反应7(35.0%)/10(50.0%)。[结论]FD伴体重减轻在常规基础上联用米氮平,效果优于联用帕罗西汀或仅常规治疗,不良反应较轻。 [Objective] To compare the curative effect of conventional treatment combined with paroxetine or mirtazapine on the weight loss of functional dyspepsia (FD). [Methods] Randomized controlled trial, 60 patients with FD and weight loss were divided into the mirtazapine group (routine therapy combined with mirtazapine), paroxetine group (conventional therapy combined with paroxetine) and the control group (routine therapy) Regular medication, outpatient referral or community follow-up. The NDI and weight of patients in each group were observed after 4 and 8 weeks. [Results] There was no significant difference in NDI and body weight between the two groups before treatment. After 4 weeks of treatment, the NDI scores of mirtazapine group and paroxetine group (control group, P <0.05) and body weight were not significantly different (P> 0.05) ; After 8 weeks of treatment, NDI score: mirtazapine group